Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Verve’s Cholesterol Gene Editing Hits Milestone – With Lilly Now Onboard

Nov 13 2023

• By Andrew McConaghie

Verve Therapeutics

Related Content

Can Beam Keep Up With Sickle Cell Gene Therapy Frontrunners? Investors Are Unconvinced

Oct 20 2023

Deal Watch: Lilly Will Take Over Beam’s Rights To Verve Cardiovascular Assets

Nov 01 2023

Lilly Plans ‘Big, Bold’ Launch For Zepbound

Nov 08 2023

Related Companies

Verve Therapeutics, Inc.

Beam Therapeutics Inc.

Eli Lilly and Company

Amgen, Inc.

Sanofi

Regeneron Pharmaceuticals, Inc.

Novartis AG

Additional Topics

Clinical Trials Companies Gene Therapy Research & Development Cardiovascular BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.